An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients

Melanoma Research

Volumn 16, Issue 4, 2006, Pages 335-340

  Mouawad, Roger ^a   Soubrane, Claude ^a   Rixe, Olivier ^a   Khayat, David ^a   Spano, Jean Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Interleukin 6; Malignant melanoma; Soluble epidermal growth factor receptor; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX RATIO; SKIN METASTASIS; TUMOR VOLUME;

EID: 33746224206     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nicholson RI, Gee JMW, Harper ME. EGF-R and cancer prognosis. Eur J Cancer 2001; 37:S9-S15.
2. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17:259-269.
3. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci USA 1984; 81:7308-7312.
4. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-643.
5. Mayes ELV, Waterfield MD. Biosynthesis of the epidermal growth factor receptor in A431 cells. EMBO J 1984; 3:531-537.
6. Partanen R, Hemminki K, Koskinen H, Luo JC. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occupat Med 1994; 36:1324-1328.
7. Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004; 87:87-95.
8. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998; 20:320-327.
9. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41:S29-S42.
10. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10:3069-3075.
11. De Wit P, Moretti S, Koenders PG, Weterman MA, van Muijen GN, Gianotti B, Ruiter DJ. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992; 99:168-173.
12. Birk D, Gansauge F, Gansauge S, Formentini A, Lucht A, Beger HG. Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 1999; 25:89-96.
13. Choi J-H, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 1997; 79:1879-1883.
14. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:129-137.
15. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumour burden. Clin Cancer Res 1996; 2:1405-1409.
16. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic malignant melanoma. J Clin Oncol 1993; 11:2173-2180.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53:457-481.
19. Gordon-Thomson C, Jones J, Mason RS, Moore GP. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005; 15:21-28.
20. Halaban R. Growth factors and melanomas. Semin Oncol 1996; 23:673-681.
21. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-554.
22. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288.
23. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999; 9:181-188.
24. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7:151-156.
25. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199-204.
26. Sasaki H, Yukiue H, Mizuno K, Sasaki H, Yukiue H, Mizuno K, et al. Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer. Int J Clin Oncol 2003; 8:79-82.
27. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2:1787-1793.
28. Zheng Z, Bepler G, Cantor A, Haura EB. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest 2005; 128:308-316.
29. Oyama N, Sekimata M, Nihei Y, Iwatsuki K, Homma Y, Kaneko F. Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin. J Dermatol Sci 1998; 16:120-128.
30. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393:83-85.
31. Marx JH 3rd, Leitzel K, Ali SM, Demers L, Almokadem S, Makhoul I, et al. Serum EGFR in metastatic breast cancer patients [abstract]. Proc ASCO 2002.
32. Jacot W, Pujol JL, Boher JM, Lamy PJ. Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br J Cancer 2004; 91:430-433.
33. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, et al. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 2005; 65:3059-3062.
34. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, et al. Soluble epidermal growth factor receptor (sEGFR)and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:306-318.
35. Gregore V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10:6006-6012.
36. Udelist G, Kostler WJ, Gschwantler-Kaulich D, Czerwenka K, Kubista E, Muller R, et al. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer 2006; 42:186-192.